Selective inhibition of TNFR1 and maintenance of beneficial effects of TNFR2-mediated protective pathways might therefore represent a promising treatment strategy for NAFLD. The gene discussed is TNFRSF1A; the disease is metabolic dysfunction-associated steatotic liver disease.